Cargando…
Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection
This contribution explores in a new statistical perspective the antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 141 coronavirus disease 2019 (COVID-19) patients exhibiting a broad range of clinical manifestations. This cohort accurately reflects the characterist...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595940/ https://www.ncbi.nlm.nih.gov/pubmed/34804064 http://dx.doi.org/10.3389/fimmu.2021.772239 |
_version_ | 1784600254421663744 |
---|---|
author | Siracusano, Gabriel Brombin, Chiara Pastori, Claudia Cugnata, Federica Noviello, Maddalena Tassi, Elena Princi, Denise Cantoni, Diego Malnati, Mauro S. Maugeri, Norma Bozzi, Carla Saretto, Gianni Clementi, Nicola Mancini, Nicasio Uberti-Foppa, Caterina Temperton, Nigel Bonini, Chiara Di Serio, Clelia Lopalco, Lucia |
author_facet | Siracusano, Gabriel Brombin, Chiara Pastori, Claudia Cugnata, Federica Noviello, Maddalena Tassi, Elena Princi, Denise Cantoni, Diego Malnati, Mauro S. Maugeri, Norma Bozzi, Carla Saretto, Gianni Clementi, Nicola Mancini, Nicasio Uberti-Foppa, Caterina Temperton, Nigel Bonini, Chiara Di Serio, Clelia Lopalco, Lucia |
author_sort | Siracusano, Gabriel |
collection | PubMed |
description | This contribution explores in a new statistical perspective the antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 141 coronavirus disease 2019 (COVID-19) patients exhibiting a broad range of clinical manifestations. This cohort accurately reflects the characteristics of the first wave of the SARS-CoV-2 pandemic in Italy. We determined the IgM, IgA, and IgG levels towards SARS-CoV-2 S1, S2, and NP antigens, evaluating their neutralizing activity and relationship with clinical signatures. Moreover, we longitudinally followed 72 patients up to 9 months postsymptoms onset to study the persistence of the levels of antibodies. Our results showed that the majority of COVID-19 patients developed an early virus-specific antibody response. The magnitude and the neutralizing properties of the response were heterogeneous regardless of the severity of the disease. Antibody levels dropped over time, even though spike reactive IgG and IgA were still detectable up to 9 months. Early baseline antibody levels were key drivers of the subsequent antibody production and the long-lasting protection against SARS-CoV-2. Importantly, we identified anti-S1 IgA as a good surrogate marker to predict the clinical course of COVID-19. Characterizing the antibody response after SARS-CoV-2 infection is relevant for the early clinical management of patients as soon as they are diagnosed and for implementing the current vaccination strategies. |
format | Online Article Text |
id | pubmed-8595940 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85959402021-11-18 Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection Siracusano, Gabriel Brombin, Chiara Pastori, Claudia Cugnata, Federica Noviello, Maddalena Tassi, Elena Princi, Denise Cantoni, Diego Malnati, Mauro S. Maugeri, Norma Bozzi, Carla Saretto, Gianni Clementi, Nicola Mancini, Nicasio Uberti-Foppa, Caterina Temperton, Nigel Bonini, Chiara Di Serio, Clelia Lopalco, Lucia Front Immunol Immunology This contribution explores in a new statistical perspective the antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 141 coronavirus disease 2019 (COVID-19) patients exhibiting a broad range of clinical manifestations. This cohort accurately reflects the characteristics of the first wave of the SARS-CoV-2 pandemic in Italy. We determined the IgM, IgA, and IgG levels towards SARS-CoV-2 S1, S2, and NP antigens, evaluating their neutralizing activity and relationship with clinical signatures. Moreover, we longitudinally followed 72 patients up to 9 months postsymptoms onset to study the persistence of the levels of antibodies. Our results showed that the majority of COVID-19 patients developed an early virus-specific antibody response. The magnitude and the neutralizing properties of the response were heterogeneous regardless of the severity of the disease. Antibody levels dropped over time, even though spike reactive IgG and IgA were still detectable up to 9 months. Early baseline antibody levels were key drivers of the subsequent antibody production and the long-lasting protection against SARS-CoV-2. Importantly, we identified anti-S1 IgA as a good surrogate marker to predict the clinical course of COVID-19. Characterizing the antibody response after SARS-CoV-2 infection is relevant for the early clinical management of patients as soon as they are diagnosed and for implementing the current vaccination strategies. Frontiers Media S.A. 2021-11-03 /pmc/articles/PMC8595940/ /pubmed/34804064 http://dx.doi.org/10.3389/fimmu.2021.772239 Text en Copyright © 2021 Siracusano, Brombin, Pastori, Cugnata, Noviello, Tassi, Princi, Cantoni, Malnati, Maugeri, Bozzi, Saretto, Clementi, Mancini, Uberti-Foppa, Temperton, Bonini, Di Serio and Lopalco https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Siracusano, Gabriel Brombin, Chiara Pastori, Claudia Cugnata, Federica Noviello, Maddalena Tassi, Elena Princi, Denise Cantoni, Diego Malnati, Mauro S. Maugeri, Norma Bozzi, Carla Saretto, Gianni Clementi, Nicola Mancini, Nicasio Uberti-Foppa, Caterina Temperton, Nigel Bonini, Chiara Di Serio, Clelia Lopalco, Lucia Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection |
title | Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection |
title_full | Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection |
title_fullStr | Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection |
title_full_unstemmed | Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection |
title_short | Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection |
title_sort | profiling antibody response patterns in covid-19: spike s1-reactive iga signature in the evolution of sars-cov-2 infection |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595940/ https://www.ncbi.nlm.nih.gov/pubmed/34804064 http://dx.doi.org/10.3389/fimmu.2021.772239 |
work_keys_str_mv | AT siracusanogabriel profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT brombinchiara profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT pastoriclaudia profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT cugnatafederica profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT noviellomaddalena profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT tassielena profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT princidenise profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT cantonidiego profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT malnatimauros profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT maugerinorma profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT bozzicarla profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT sarettogianni profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT clementinicola profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT mancininicasio profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT ubertifoppacaterina profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT tempertonnigel profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT boninichiara profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT diserioclelia profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection AT lopalcolucia profilingantibodyresponsepatternsincovid19spikes1reactiveigasignatureintheevolutionofsarscov2infection |